 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

Kronos Bio, Inc. (NASDAQ:KRON  Get Free Report) CEO Norbert W. Bischofberger bought 97,935 shares of the stock in a transaction on Friday, November 17th. The stock was bought at an average...

Kronos Bio, Inc. (NASDAQ:KRON) CEO Acquires $105,769.80 in Stock

Kronos Bio GAAP EPS of -$0.54 misses by $0.03, revenue of $0.92M misses by $0.48M...

Kronos Bio GAAP EPS of -$0.54 misses by $0.03, revenue of $0.92M misses by $0.48M

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kronos Bio reports Q3 EPS (54c), consensus (51c)

Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences Optimization of resource allocation...

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Kronos Bio, Inc. (NASDAQ:KRON  Get Free Report)s stock price fell 5.2% during mid-day trading on Monday . The stock traded as low as $0.86 and last traded at $0.87. 226,319 shares...

Kronos Bio (NASDAQ:KRON)  Shares Down 5.2%

Kronos Bio to reduce workforce by 19% in restructuring

Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study Restructuring plan extends...

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical...

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting SAN MATEO, Calif., and CAMBRIDGE, Mass...

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Watchers	417
52-Wk Low	$0.731
52-Wk High	$2.84

Market Cap	$68.81M
Volume (M)	77,444.00
52-Wk High	$2.84
52-Wk Low	$0.731

KRON Kronos Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals